Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Circulating pre-diagnostic metabolites and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: a population-based study of 12 cohorts.

Journal of the National Cancer Institute·2026
Same author

Adherence to the Mediterranean diet and risk of pancreatic cancer: an analysis of 2.3 million participants in the Pooling Project of Prospective Studies of Diet and Cancer (DCPP).

European journal of epidemiology·2026
Same author

Artificially Sweetened and Sugar-Sweetened Beverage Intake and Risk of Liver Cancer.

JAMA network open·2026
Same author

Polygenic risk score with KLK3 SNP-SNP interaction pairs for predicting prostate cancer aggressiveness.

Communications medicine·2026
Same author

Germline polygenic score for prostate cancer aggressiveness.

medRxiv : the preprint server for health sciences·2026
Same author

A Gene Expression Tumor Signature Optimizing Partial Area-Under-the-Curve (pAUC) to Improve Specificity for Indolent Prostate Cancer.

The Prostate·2026

Related Experiment Video

Updated: May 26, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Prognostic determinants in prostate cancer.

Neil E Martin1, Lorelei A Mucci, Massimo Loda

  • 1Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, MA, USA.

Cancer Journal (Sudbury, Mass.)
|December 14, 2011
PubMed
Summary
This summary is machine-generated.

Identifying reliable prognostic markers is crucial for managing prostate cancer due to its varied outcomes. This review examines existing and emerging clinical and molecular factors to improve patient prognosis and guide treatment decisions.

More Related Videos

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Related Experiment Videos

Last Updated: May 26, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Area of Science:

  • Oncology
  • Urology
  • Molecular Pathology

Background:

  • Prostate cancer exhibits heterogeneous clinical outcomes, necessitating effective prognostic markers.
  • Despite extensive research, few clinical, pathological, molecular, or genetic factors are routinely used for prognosis.
  • Understanding molecular pathogenesis offers potential for next-generation prognostic markers.

Purpose of the Study:

  • To review current clinical and molecular prognostic determinants in prostate cancer.
  • To highlight the need for robust markers to guide optimal management.
  • To discuss the potential of emerging molecular factors.

Main Methods:

  • Literature review of clinical, pathological, molecular, and genetic factors.
  • Analysis of established and investigational prognostic markers.
  • Synthesis of current understanding of prostate cancer pathogenesis.

Main Results:

  • Heterogeneity in prostate cancer outcomes presents a challenge for prognosis.
  • A limited number of investigated factors are currently employed in routine clinical practice.
  • Molecular pathogenesis research is paving the way for advanced prognostic tools.

Conclusions:

  • Accurate prognosis is essential for effective prostate cancer management.
  • Next-generation prognostic markers derived from molecular insights hold significant promise.
  • Further research is needed to validate and implement novel prognostic determinants.